Golimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TNFα |
| Clinical data | |
| Trade names | Simponi |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a610010 |
| Licence data | EMA:Link, US FDA:link |
| Legal status |
|
| Routes of administration | Subcutaneous injection |
| Identifiers | |
| CAS Number |
476181-74-5  |
| ATC code | L04AB06 |
| ChemSpider | none |
| UNII |
91X1KLU43E  |
| KEGG |
D04358 |
| ChEMBL |
CHEMBL1201833 |
| Chemical data | |
| Formula | C6530H10068N1752O2026S44 |
| Molar mass | 147 kg/mol |
| (what is this?) (verify) | |
Golimumab (CNTO 148)[1] is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[2] and hence is a TNF inhibitor.
Golimumab was developed by Centocor and is approved in Canada[3] and the United States[4] as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.[5][6] Golimumab has been approved in 2013 for use in adults with moderately to severely active ulcerative colitis.
In the same year, Johnson & Johnson, the parent company of Centocor, also received an approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[7] Golimumab is marketed by Merck & Co, Inc. in Europe, pending final arbitration between J&J and Merck.[8][9][10]
Clinical trials
Rheumatoid arthritis
Large, double-blind randomized controlled trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone.[11]
References
- ↑ Mazumdar, Sohini; David Greenwald (2009). "Golimumab". mAbs 1 (5): 422–431. doi:10.4161/mabs.1.5.9286.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab, American Medical Association.
- ↑ "Health Canada Approves Simponi (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis". Apr 2009
- ↑ FDA Approves Simponi
- ↑ "FDA clears potential blockbuster arthritis drug". North County Times (Lee Enterprises). Associated Press. 24 April 2009. Retrieved 23 October 2010.
- ↑ Maxwell, LJ; Zochling, J; Boonen, A; Singh, JA; Veras, MM; Tanjong Ghogomu, E; Benkhalti Jandu, M; Tugwell, P; Wells, GA (18 April 2015). "TNF-alpha inhibitors for ankylosing spondylitis.". The Cochrane database of systematic reviews 4: CD005468. PMID 25887212.
- ↑ Johnson & Johnson Reports 2008 First-Quarter Results
- ↑ FDA approves Johnson & Johnson rheumatoid arthritis drug golimumab
- ↑ Merck sees fast ruling in J&J Remicade arbitration
- ↑ "Simponi European Public Assessment Report". European Medicines Agency. Retrieved 2009-11-15.
- ↑ Oldfield V, Plosker GL..Biodrugs 2009;23(2):125-135. doi:10.2165/00063030-200923020-00005.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||